睿知中国医院研究地图
候选清单

正在招募肺癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 24 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 24

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
  2. 研究中心中国医学科学院肿瘤医院深圳医院Cancer Hospital CAMS – Shenzhen深圳医院页面
  3. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  4. 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
  5. 研究中心广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面
  6. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  7. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  8. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  9. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  10. 研究中心佛山市第一人民医院First People's Hospital of Foshan佛山医院页面
  11. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  12. 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
  13. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  14. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  15. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  16. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  17. 研究中心Nanjing Chest Hospital南京医院页面
  18. 研究中心江苏省苏北人民医院Northern Jiangsu People's Hospital扬州医院页面
  19. 研究中心山西白求恩医院Shanxi Bethune Hospital太原医院页面
  20. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  21. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  22. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  23. 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
  24. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07143045,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed NSCLC with EGFR sensitizing mutations (including L858R or Exon 19Del), ineligible for curative surgery or radiotherapy.

    入选标准第 2 条

    CNS metastases diagnosed as brain metastases (BM) and/or leptomeningeal metastases (LM) by imaging and/or cerebrospinal fluid pathological examination.

    入选标准第 3 条

  3. . All patients must be stable without any systemic (oral or parenteral) corticosteroid or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated.

    入选标准第 8 条

    . Patients who have received any investigational drug, biological therapy, or immunotherapy for their malignant tumors within the past 21 days.

    排除标准第 5 条

    . Patients who have received radiation to more than 30% of the bone marrow within 2 weeks before the first dose of study treatment.

    排除标准第 9 条

    . Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of study treatment) certain medications or herbal supplements that are known to be potent inhibitors or inducers of CYP3A4/5 (see Appendix A).

    排除标准第 10 条

    . Patients with unstable and symptomatic metastases: Any unstable and symptomatic CNS or distant metastasis that is not symptomatically controlled by prior surgery, radiotherapy or corticosteroid therapy within 2 weeks of initial study treatment.

    排除标准第 16 条

    . Any unresolved toxicities from prior therapy, greater than Common Terminology Criteria for Adverse Events (CTCAE 5.0) Grade 1 at the time of starting study treatment, with exception of alopecia.

    排除标准第 17 条

  4. . ECOG performance status 0 or 1, with no deterioration over the past 2 weeks, and expected survival time ≥ 3 months.

    入选标准第 10 条

  5. Absolute neutrophil count <1.5 × 109/L.

    排除标准第 28 条

    Platelet count <100 × 109/L (Transfusion-dependent patients are excluded from this study).

    排除标准第 29 条

    Hemoglobin <90 g/L.

    排除标准第 30 条

    Alanine aminotransferase (ALT) > 2.5 times the upper limit of normal (ULN) in the absence of documented metastases to liver or > 5 times the ULN in the presence of metastases to liver.

    排除标准第 31 条

    Aspartate aminotransferase (AST) > 2.5 times the ULN in the absence of documented metastases to liver or > 5 times the ULN in the presence of metastases to liver.

    排除标准第 32 条

    Total bilirubin > 1.5 times the ULN in the absence of metastases to liver or >3 times the ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or metastases to liver.

    排除标准第 33 条

    Creatinine >1.5 times the ULN concurrent with creatinine clearance <50 mL/min (measured or calculated by Cockcroft-Gault equation). Confirmation of creatinine clearance is only required when creatinine is >1.5 times the ULN.

    排除标准第 34 条

  6. . Presence of only leptomeningeal metastases (LM) disease confirmed by MRI and/or positive cerebrospinal fluid (CSF) pathology, with no brain metastases (BM).

    排除标准第 7 条

  7. . History of concurrent and/or other active malignant tumors requiring treatment within 5 years of study treatment, excluding prior treated squamous cell carcinoma or basal cell carcinoma or carcinoma in situ.

    排除标准第 12 条

    . Patients who have received any anti-neoplastic herbal medicines for their malignant tumors within the past 2 weeks.

    排除标准第 40 条

  8. . Women of child-bearing potential (WOCBP) and male patients should agree to take medically acceptable contraception measures while on study treatment and for 3 months following completion of study treatment. All WOCBP must have a negative pregnancy test at screening.

    入选标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07143045,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male or female, aged ≥18 years.
  2. Histologically or cytologically confirmed NSCLC with EGFR sensitizing mutations (including L858R or Exon 19Del), ineligible for curative surgery or radiotherapy.
  3. CNS metastases diagnosed as brain metastases (BM) and/or leptomeningeal metastases (LM) by imaging and/or cerebrospinal fluid pathological examination.
  4. Planning to receive zorifertinib (zorifertinib group) or other anti-tumor treatments (other treatment group) as first-line treatment.
  5. Voluntarily agreeing to participate in this study and signing the informed consent form.
  6. . No prior treatment with chemotherapy, EGFR-TKIs, biological therapy, immunotherapy, or any investigational drug that is considered first line treatment for advanced NSCLC.
  7. . Eligible patients are not candidates for definitive surgical resection or radiation of all lesions in the opinion of the treating physician.
  8. . All patients must be stable without any systemic (oral or parenteral) corticosteroid or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated.
  9. . Patients may have prior placement of a properly functioning CNS shunt or Ommaya reservoir.
  10. . ECOG performance status 0 or 1, with no deterioration over the past 2 weeks, and expected survival time ≥ 3 months.
  11. . Women of child-bearing potential (WOCBP) and male patients should agree to take medically acceptable contraception measures while on study treatment and for 3 months following completion of study treatment. All WOCBP must have a negative pregnancy test at screening.
  12. . Patients with measurable CNS lesions must have at least one site of CNS lesion, which has not been previously irradiated, can be accurately measured at baseline as ≥ 10 mm in the longest diameter by MRI, and is suitable for accurate repeated measurements. Measurable extracranial lesions are not required. Patients with non-measurable CNS lesions must have at least one extracranial lesion, which has not been previously irradiated, can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except for lymph nodes which must have a short diameter ≥ 15 mm) by CT/MRI, and is suitable for accurate repeated measurements.

排除标准:Exclusion Criteria:

  1. Currently participating or planning to participate in any interventional clinical study for first-line treatment (patients who have participated in non-interventional, real-world studies may still be included).
  2. Other reasons that, in the Investigator's opinion, make the patient unsuitable for this study.
  3. . Prior treatment with EGFR-TKIs (if EGFR-TKIs were used as adjuvant therapy, patients may be enrolled if the time from discontinuation to relapse meets the following requirements: >6 months for Cohort A, and >3 months for Cohorts B and C).
  4. . Positive for T790M mutation documented by central or local laboratory using an approved or validated test method, or documented positive KRAS or cMET.
  5. . Patients who have received any investigational drug, biological therapy, or immunotherapy for their malignant tumors within the past 21 days.
  6. . Patients who have had a major surgical procedure (excluding the need for placement of vascular access or a CNS shunt), or significant traumatic injury within 4 weeks of the first dose of study treatment, or have an anticipated need for major surgery during the study.
  7. . Presence of only leptomeningeal metastases (LM) disease confirmed by MRI and/or positive cerebrospinal fluid (CSF) pathology, with no brain metastases (BM).
  8. . Prior radiation therapy for CNS metastases that involves measurable or non-measurable sites of disease to assess efficacy.
  9. . Patients who have received radiation to more than 30% of the bone marrow within 2 weeks before the first dose of study treatment.
  10. . Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of study treatment) certain medications or herbal supplements that are known to be potent inhibitors or inducers of CYP3A4/5 (see Appendix A).
  11. . Unmanageable nausea and vomiting, chronic gastrointestinal diseases, or prior gastric resection or surgical procedure that may interfere with adequate absorption of study drug.
  12. . History of concurrent and/or other active malignant tumors requiring treatment within 5 years of study treatment, excluding prior treated squamous cell carcinoma or basal cell carcinoma or carcinoma in situ.
  13. . History of any type of documented interstitial lung disease or radiation pneumonitis.
  14. . Presence of any severe or uncontrolled systemic disease or condition, including: (i) uncontrolled hypertension or diabetes; (ii) serious cardiac, pulmonary or renal disorders; (iii) active bleeding diatheses; (iv) any active type of bacterial, viral, fungal or other infection that would pose a significant risk to the patient in the opinion of the Investigator; or (v) active hepatitis B virus positive (defined as hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive, and hepatitis B DNA positive (or detectable) or above the cut-off value) or positive HCV antibodies or positive HIV test result.
  15. . Women who are pregnant or lactating. WOCBP and fertile men with a WOCBP-partner not using adequate contraception measures.
  16. . Patients with unstable and symptomatic metastases: Any unstable and symptomatic CNS or distant metastasis that is not symptomatically controlled by prior surgery, radiotherapy or corticosteroid therapy within 2 weeks of initial study treatment.
  17. . Any unresolved toxicities from prior therapy, greater than Common Terminology Criteria for Adverse Events (CTCAE 5.0) Grade 1 at the time of starting study treatment, with exception of alopecia.
  18. . Patients with a significant cardiovascular disorder or condition, including any of the following:
  19. Congestive heart failure (CHF) currently requiring treatment and patients with New York Heart Association (NYHA) Class III/IV CHF (see Appendix B).
  20. Need for antiarrhythmic drug therapy for a ventricular arrhythmia or patients with uncontrolled or unstable arrhythmias.
  21. Severe conduction disturbance (e.g., second- or third-degree AV block).
  22. Angina pectoris requiring treatment.
  23. QTc interval > 450 msec (males) or > 470 msec (females).
  24. History of congenital long QT syndrome, congenital short QT syndrome, Torsades de Pointes, or Wolff Parkinson White syndrome.
  25. Left ventricular ejection fraction (LVEF) <50% as determined by echocardiography or MUGA scan.
  26. Myocardial infarction diagnosed within the past 6 months.
  27. . Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
  28. Absolute neutrophil count <1.5 × 109/L.
  29. Platelet count <100 × 109/L (Transfusion-dependent patients are excluded from this study).
  30. Hemoglobin <90 g/L.
  31. Alanine aminotransferase (ALT) > 2.5 times the upper limit of normal (ULN) in the absence of documented metastases to liver or > 5 times the ULN in the presence of metastases to liver.
  32. Aspartate aminotransferase (AST) > 2.5 times the ULN in the absence of documented metastases to liver or > 5 times the ULN in the presence of metastases to liver.
  33. Total bilirubin > 1.5 times the ULN in the absence of metastases to liver or >3 times the ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or metastases to liver.
  34. Creatinine >1.5 times the ULN concurrent with creatinine clearance <50 mL/min (measured or calculated by Cockcroft-Gault equation). Confirmation of creatinine clearance is only required when creatinine is >1.5 times the ULN.
  35. If bone metastases are present and liver function is otherwise considered adequate by the Investigator, then isolated elevated alkaline phosphatase (ALP) is not an exclusion criterion.
  36. . History of hypersensitivity to active or inactive excipients of the study drug or drugs with a similar chemical structure or class to the study drug.
  37. . Judgment by the Investigator that the patient should not participate in the study if the patient is unwilling to comply with all study procedures and treatment.
  38. . History of recent stroke (<6 months), or prior central nervous system injury that has persistent neurologic deficits that would affect neurologic assessments.
  39. . Significant medical or psychiatric illness that would interfere with the compliance to the protocol and ability to tolerate treatment.
  40. . Patients who have received any anti-neoplastic herbal medicines for their malignant tumors within the past 2 weeks.

引自 ClinicalTrials.gov, NCT07143045, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07143045,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07143045